Revenue: The sum of all revenue fields included for a company's operating activities.
Alnylam Pharmaceuticals, Inc. (ALNY) had Revenue of $594.19M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
$594.19M |
$-57.48M |
|
$71.04M |
|
$523.15M |
|
$576.11M |
|
$18.08M |
|
$-59.67M |
|
$-41.60M |
|
$-41.60M |
|
$-57.48M |
|
$-57.48M |
|
$-57.48M |
|
$-57.48M |
|
$18.08M |
|
$32.48M |
|
129.68M |
|
129.68M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$3.27B |
|
$498.68M |
|
$945.55M |
|
$4.21B |
|
$1.08B |
|
$1.03B |
|
$3.02B |
|
$4.10B |
|
$115.44M |
|
$115.44M |
|
$115.44M |
|
130.31M |
|
| Cash Flow Statement Financials | |
$-118.31M |
|
$113.77M |
|
$44.08M |
|
$968.65M |
|
$1.02B |
|
$53.60M |
|
$56.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.04 |
|
-- |
|
-- |
|
0.90 |
|
8.88 |
|
88.04% |
|
3.04% |
|
3.04% |
|
-- |
|
-7.00% |
|
-9.67% |
|
$-127.28M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
1.08 |
|
1.42 |
|
63.32 |
|
-49.79% |
|
-49.79% |
|
-1.36% |
|
-5.04% |
|
$0.89 |
|
$-0.98 |
|
$-0.91 |
|